Impact on the PK of CYP Substrates with Increasing IL-6 after Administration of the TCB, Glofitamab

Topics Covered:
• Review summary of IL-6 impact on CYP isoforms
• Review summary of PBPK modelling of cytokines including IL-6
• IL-6 levels and Cytokine Release Syndrome in the ICI setting
• DDI assessment via PBPK modeling of glofitamab-induced IL-6 levels
Certara accelerates medicines to patients using proprietary biosimulation software and technology to transform traditional drug discovery and development. Its clients include 1,600 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 60 countries.
Please visit us at www.certara.com/